Compare LYFT Inc (LYFT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs TG Therapeutics Inc — how do they compare? LYFT Inc trades at $16.16 (market cap $6.11B), while TG Therapeutics Inc trades at $54.91 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and TG Therapeutics Inc for 15 Days on average.
| LYFT | TGTX | |
|---|---|---|
Market Cap | $6.11B | $8.16B |
Volume | 13,504,560 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $24.57 | $59.06 |
52-Week Low | $12.65 | $26.94 |
Typical Hold Time | 47 Days | 15 Days |
Enterprise Value | $5.57B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.27, up 4.29% with bullish technical signals from moving averages and ADX indicators. The company shows remarkable financial improvement with 2025 revenue of $6.32B and net income of $2.84B, achieving a 45.02% profit margin. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.35 and P/S of 0.96, though EV/EBITDA remains elevated at 34.55.
Lyft presents a mixed investment case with strong profitability growth offset by competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces challenges from driver classification lawsuits and market saturation concerns. Recent earnings misses and high RSI levels suggest near-term volatility despite positive cash flow trends and institutional support.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
